UPDATE ON THE MANAGEMENT OF
Genitourinary Malignancies
November 1-2, 2019The University of Texas MD Anderson Cancer Center Dan L. Duncan Building (CPB) Floor 8, Rooms 1-8 1155 Pressler Street Houston, Texas
Program Directors
Jose A. Karam, MD (Chair)Associate ProfessorUrology
Matthew T. Campbell, MD (Co-Chair)Assistant ProfessorGenitourinary Medical Oncology
Brian F. Chapin, MD (Co-Chair)Associate ProfessorUrology
14th
FocusThis conference will highlight innovative, multidisciplinary and novel treatment approaches for the treatment of complex genitourinary malignancies for the practicing urologist and medical oncologist that might not be currently either available or feasible in their home practice.
This activity will also inform practicing urologists and medical oncologists on ongoing research (clinical and translational) that will lead to further developments in our field that will lead to potentially fundamental changes in the treatment paradigm for patients with genitourinary malignancies.
The long-term goals of this activity are that attendees are better equipped to treat patients with genitourinary malignancies, that there is an increased awareness of new developments and research in the and an increased utilization of multidisciplinary approaches to the treatment of patients.
Educational ObjectivesAfter attending the conference, participants should be able to:
• Evaluate, counsel and treat patients with rare genitourinary malignancies (penile cancer, testicular cancer, and germ cell tumors) (Knowledge, Competence, Performance, Patient Outcomes);
• Utilize surgery and therapies for patients with kidney cancer (small renal masses, locally advanced tumors/adjuvant therapy, metastatic tumors/cytoreductive surgery, and systemic therapy) (Knowledge, Competence, Performance, Patient Outcomes);
• Assess patients with urothelial carcinoma (molecular characterization, non-muscle invasive tumors, muscle-invasive tumors, and systemic therapy) (Knowledge, Competence);
• Evaluate, counsel and treat patients with prostate cancer (screening, early disease/focal therapy, radiation therapy, high-risk disease, and recurrent/metastatic disease) (Knowledge, Competence, Performance, Patient Outcomes).
UPDATE ON THE MANAGEMENT OF
Genitourinary Malignancies14th
Educational MethodsLecture/Didactic – Case Study – Panel Discussion – Question and Answer Sessions – Poster Session – Skills- Based Training
Target AudienceThis conference should be of value to Urologists, Medical Oncologists, Physician Assistants, and Advanced Nurse Practitioners.
EvaluationA course evaluation will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.
Accreditation/Credit DesignationPHYSICIANS
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 15.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ETHICSThe session entitled, Heritable Genitourinary Cancers-When to Screen and What to Do Next, has been designated by The University of Texas MD Anderson Cancer Center for 1.00 AMA PRA Category 1 Credits™ in medical ethics and/or professional responsibility.
CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES
Certificates awarding AMA PRA Category 1 Credits™ or certificates documenting attendance will be emailed when an individual completes the online CME Verification process after the conference.
UPDATE ON THE MANAGEMENT OF
Genitourinary Malignancies
CALL FOR AbstractsAbstracts will be selected for poster presentation at the conference.
Please submit abstracts via e-mail to [email protected].
MD Anderson Organizing CommitteePROGRAM DIRECTORS
Jose A. Karam, MD (Chair)Associate ProfessorUrology
Matthew T. Campbell, MD (Co-Chair)Assistant ProfessorGenitourinary Medical Oncology
Brian F. Chapin, MD (Co-Chair)Associate ProfessorUrology
CONFERENCE COMMITTEE
Ana Aparicio, MDAssociate ProfessorGenitourinary Medical Oncology
John Davis, MDAssociate Professor Urology
Neema Navai, MDAssociate Professor Urology
Curtis A. Pettaway, MDProfessorUrology
Amishi Shah, MDAssistant ProfessorGenitourinary Medical Oncology
Arlene Siefker-Radtke, MDProfessorGenitourinary Medical Oncology
Nizar M. Tannir, MDProfessor and Ad-Interim ChairmanGenitourinary Medical Oncology
Christopher G. Wood, MDProfessor and Vice ChairmanUrology
Carol FourtuniaAdministrative CoordinatorUrology
Allison Baring, CMPCME Conference PlannerCME Conference Management
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.
Photographing, audio taping and videotaping are prohibited.
AGENDAFriday November 1, 2019
7:00 am Registration/Continental Breakfast
7:50 Welcome/Opening Remarks Jose A. Karam, MD; Matthew T. Campbell, MD and Brian F. Chapin, MD
SESSION I: Renal Cell CarcinomaModerators:Christopher G. Wood, MD and Nizar M. Tannir, MD
Management of the Small Renal Mass: What is the Best Approach?
8:00 Active Surveillance Surena Matin, MD
8:10 Ablation Kamran Ahrar, MD
8:20 Partial Nephrectomy Jeffrey J. Tomaszewski, MD
8:30 Question and Answer Session
Locally Advanced Renal Cell Carcinoma
8:45 Is There a Role for Neoadjuvant Therapy in the Management of Locally Advanced Renal Cell Carcinoma? Christopher G. Wood, MD
9:00 Update on Adjuvant Therapy in Kidney Cancer: Recent Results and Ongoing Trials Jose A. Karam, MD
9:15 Question and Answer Session
9:30 Break
Metastatic Renal Cell Carcinoma: What is the Best First-Line Systemic Therapy for Intermediate/Poor Risk Clear-Cell RCC?
9:45 A PD-1 or PD-L1 Antibody + VEGF Targeted Therapy Matthew T. Campbell, MD
9:55 Nivolumab + Ipilimumab Jianjun Gao, MD, PhD
What is the Best First-Line Systemic Therapy for Favorable-Risk Clear-Cell RCC?
10:05 PD-1 or PD-L1 Antibody + VEGF Targeted Therapy Amishi Shah, MD
10:15 A Sequential Therapy of VEGFR-TKI Followed by Immune Checkpoint Inhibitor(s) Pavlos Msaouel, MD, PhD
10:25 Debate on the Role of Cytoreductive Nephrectomy (CN) in the Era of Immune Checkpoint Inhibitors and Targeted Therapies
Pro: There is Still a Role for CN in the Era of Immune Checkpoint Inhibitors (ICI) and Targeted Therapies Robert Uzzo, MD
Con: CN Should No Longer be Considered Standard of Care in the Era of ICI and Targeted Therapies Eric Jonasch, MD
10:50 Update on Systemic Therapy for Non-Clear Cell Renal Cell Carcinoma: Have We Made Any Progress? Nizar M. Tannir, MD
11:05 Question and Answer Session
11:20 Case Presentations Moderator: Christopher G. Wood, MD Panelists: Kamran Ahrar, MD; Jianjun Gao, MD, PhD; Eric Jonasch, MD;
Jose A. Karam, MD; Surena Matin, MD; Amishi Shah, MD; Nizar M. Tannir, MD; Jeffrey J. Tomaszewski, MD and Robert Uzzo, MD
12:05 pm Lunch (Provided)
SESSION II: Rare GU TumorsModerators: Curtis A. Pettaway, MD and Amishi Shah, MD
Advanced Urethral Cancer- What is the Best Local Control Strategy? Case of Advanced Urethral Tumor
1:00 Chemotherapy Role and Considerations Amishi Shah, MD
1:10 Consolidation Residual Disease
Radiation is Best Patricia J. Eifel, MD
Surgery is Best Curtis A. Pettaway, MD
Case of Advanced Urethral Tumor-Continued Advanced Penile Cancer
1:30 Role of Adjuvant Radiotherapy in Penile Cancer-Who Benefits? Karen Hoffman, MD
1:45 Update on the InPACT Trial Curtis A. Pettaway, MD
2:00 When Chemotherapy Fails- What’s Next? Jad Chahoud, MD
2:15 Question and Answer Session
2:30 Break
Advanced Germ Cell Tumor
3:00 Postchemotherapy RPLND for Germ Cell Tumors: Indications, Outcomes and Complications Jose A. Karam, MD
3:15 Stem cell Transplant in Advanced GCT Yago Nieto, MD, PhD
3:30 Case Presentations Matthew T. Campbell, MD
3:50 Break
4:00 Andrew C. von Eschenbach Lecture Series Robert Uzzo, MD
Distinguished Alumni Lectures
4:40 Department of Urology David A. Swanson Distinguished Alumni Lecture Series M. Derya Balbay, MD (Class of 1999)
Department of GU Medical Oncology Vasiliki Tzelepi, MD (Class of 2010)
5:30 pm Adjourn/Reception
Saturday November 2, 2019
7:00 am Registration/Continental Breakfast
7:50 Welcome/Opening Remarks Jose A. Karam, MD; Matthew T. Campbell, MD and Brian F. Chapin, MD
SESSION III: Bladder/Upper Tract CancersModerators: Neema Navai, MD and Arlene O. Siefker-Radtke, MD
Upper Tract Urothelial Carcinoma
8:00 Clinical and Translational Updates in Upper Tract Urothelial Carcinoma Surena Matin, MD
Non-Muscle-Invasive Bladder Cancer (NMIBC) and Muscle-Invasive-Bladder Cancer (MIBC)
8:15 Clinically Node Positive Bladder Cancer- When Should Surgery Be Applied? Neema Navai, MD
8:30 Can Some Patients with MIBC be Cured with Systemic Therapy Alone? Matthew T. Campbell, MD
8:45 Trimodal Therapy or Radical Cystectomy: Which Provides Best Local Control?
Trimodal Therapy Chad Tang, MD
Radical Cystectomy H. Barton Grossman, MD
9:05 Challenges and Opportunities in the BCG Shortage Era Ashish Kamat, MD
9:20 Gene Therapy for Bladder Cancer – From Bench to Bedside Colin P. Dinney, MD
9:35 Case Presentations: NMIBC Neema Navai, MD
9:45 Case Presentations: MIBC Ashish Kamat, MD
9:55 Question and Answer Session
10:05 Break
* Indicates ethics credit
Metastatic Urothelial Carcinoma
10:25 New Agents/New Approvals: Where Do We Go From Here? Arlene O. Siefker-Radtke, MD
10:40 Combination IO trials in Metastatic Urothelial Carcinoma -Translational and Clinical Data Jianjun Gao, MD, PhD
10:55 When C-Met Inhibitors and UC Meet: Early Evidence for Clinical Activity Pavlos Msaouel, MD, PhD
11:05 Challenging Cases in Metastatic UC and IO Toxicity Matthew T. Campbell, MD
11:25 Question and Answer Session
11:35 Break
SESSION IV: Prostate CancerProstate Biopsy Seminar-Multidisciplinary Approach
11:50 MRI Based Selection for Fusion Prostate Biopsy—Interpretation Haesun Choi, MD
12:00 pm Prostate Fusion Biopsy- How I Do It John F. Ward, MD
12:15 Transperineal Free Hand Biopsy- How I Do It Lisly J. Chery, MD
12:30 Case Presentations
12:45 Question and Answer Session
1:00 Ethics Lecture (Lunch provided) Heritable Genitourinary Cancers-When to Screen and What to Do Next?* Ashley H. Woodson, MS
Radiation Therapy in Prostate Cancer
2:00 Proton Therapy for Prostate Cancer – Long Term Results Chad Tang, MD
2:15 The Role of Site-Directed Radiation Therapy in Metastatic Patients Quynh-Nhu Nguyen, MD
2:30 Question and Answer Session
High-Risk Prostate Cancer
2:40 Role of PET Imaging in Prostate Cancer Aradhana M. Venkatesan, MD
2:55 The Punch Trial is out...What Next? Brian F. Chapin, MD
3:10 Clinical Trials for High-Risk Clinically Localized Disease Eleni Efstathiou, MD, PhD
3:25 Salvage Robotic Assisted Radical Prostatectomy – State of the Art Louis L. Pisters, MD
3:40 Case Presentations
Recurrent/Metastatic Prostate Cancer
4:00 Management of Biochemical Relapse Post RP/RT Justin R. Gregg, MD
4:15 Systemic Therapy for Hormone Naïve Metastatic Prostate Cancer Ana Aparicio, MD
4:30 Question and Answer Session
4:45pm Adjourn
MD Anderson Faculty Kamran Ahrar, MDProfessorInterventional Radiology
Ana Aparicio, MDAssociate ProfessorGenitourinary Medical Oncology
Matthew T. Campbell, MD (Co-Chair)Assistant ProfessorGenitourinary Medical Oncology
Brian F. Chapin, MD (Co-Chair)Associate ProfessorUrology
Lisly J. Chery, MDAssistant ProfessorUrology Surgery-Sugar Land
Haesun Choi, MDProfessorAbdominal Imaging Department
Colin P. Dinney, MDChair Urology
Eleni Efstathiou, MD, PhDAssociate ProfessorGenitourinary Medical Oncology
Patricia J. Eifel, MDProfessorRadiation Oncology
Jianjun Gao, MD, PhDAssistant ProfessorGenitourinary Medical Oncology
Justin R. Gregg, MDAssistant ProfessorUrology
H. Barton Grossman, MDClinical ProfessorUrology
Karen Hoffman, MDAssociate ProfessorRadiation Oncology
Eric Jonasch, MDProfessorGenitourinary Medical Oncology
Ashish Kamat, MDProfessorUrology
Jose A. Karam, MD (Chair)Associate ProfessorUrology
Surena Matin, MDProfessor Urology
Pavlos Msaouel, MD, PhDAssistant ProfessorGenitourinary Medical Oncology
Neema Navai, MDAssociate ProfessorUrology
Quynh-Nhu Nguyen, MDAssociate ProfessorRadiation Oncology
Yago Nieto, MD, PhDProfessorStem Cell Transplantation
Curtis A. Pettaway, MDProfessorUrology
Louis L. Pisters, MDProfessorUrology
Amishi Shah, MDAssistant ProfessorGenitourinary Medical Oncology
Arlene O. Siefker-Radtke, MDProfessorGenitourinary Medical Oncology
Chad Tang, MDAssistant ProfessorRadiation Oncology
Nizar M. Tannir, MDProfessor and Ad-Interim ChairmanGenitourinary Medical Oncology
Aradhana M. Venkatesan, MDAssociate ProfessorAbdominal Imaging Department
John F. Ward, MDProfessor Urology
Ashley H. Woodson, MSSenior Genetic CounselorClinical Cancer Genetics
Christopher G. Wood, MDProfessor and Vice-ChairmanUrology
Guest FacultyJad Chahoud, MDMoffitt Cancer CenterTampa, Florida
Jeffrey J. Tomaszewski, MDDirectorGenitourinary Oncology ProgramMD Anderson Cancer Center at CooperCamden, New Jersey
Andrew C. von Eschenbach Lecture SeriesRobert Uzzo, MD, FACSChairSurgical OncologyG. Willing "Wing" Pepper ChairCancer ResearchKidney, Bladder, and Prostate Cancer TRDG MemberSenior Vice-PresidentPhysician ServicesPresidentFox Chase Cancer Center Medical Group, Inc.Professor of SurgeryTemple University Health SystemPhiladelphia, Pennsylvania
Distinguished Alumni Lectures
Department of Urology
David A. Swanson Distinguished Alumni Lecture SeriesM. Derya Balbay, MDProfessorUrologyKOC University HospitalIstanbul, Turkey
Department of GU Medical OncologyVasiliki Tzelepi, MDAssistant ProfessorPathologyUniversity of PatrasPatras, Greece
Registration InformationOn-site registration opens at 7:00 am on Friday, November 1. The conference will begin at 7:50 am and adjourn at 4:45 pm on Saturday, November 2. Advanced registration is encouraged as space and materials are limited.
The deadline for advanced registration is Friday, October 11, 2019.
There are three ways to register:
1. On-line at www.mdanderson.org/conferences2. Fax to: 713-794-17243. Mail to: CME/Conference Management
Unit 1781 The University of Texas MD Anderson Cancer Center P.O. Box 301407 Houston, TX 77230-1407
We accept the following forms of payment:• Check (payable through U.S. banks only)• Money Order• Credit Cards (MasterCard, VISA, and American Express)• Cash (on-site registration only)
A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, lunch and a reception. Please refer to the registration form for specific information regarding fees.
REFUND/CANCELLATION POLICY
The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before October 11, 2019. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.
CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.
CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.
For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.
SPECIAL ASSISTANCE
Contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.
ACCOMMODATIONS
• A block of rooms has been reserved for conference attendees at the InterContinental Houston – Medical Center located at 6750 Main Street, Houston, Texas.
• Book your room online at: https://bit.ly/2Yv1aWt
• The hotel phone number is (713) 422-2779.
• Early hotel reservation is suggested and the room block cutoff date is Thursday, October 10, 2019.
• When you make reservations, be sure to mention the group name: 14th Update on the Management of Genitourinary Malignancies Conference to be assured of receiving the special meeting rate of $179/nigh for a single/double guest room. Please add 17% Texas state and local taxes.
GROUND TRANSPORTATION (prices are subject to change and variable depending on location of conference)
• Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). The following forms of ground transportation are available to and from both airports:
• Uber or Lyft • Yellow Cab- 713.236.1111 • Super Shuttle: For more information, call toll free at 800.258.3826 or visit
www.supershuttle.com
Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.
CO
NFE
REN
CE
REG
ISTR
ATI
ON
- 17
6700
/30/
1217
19/4
114
th U
pdat
e on
the
Man
agem
ent o
f Gen
itour
inar
y M
alig
nanc
ies
Nove
mbe
r 1-2
, 201
9La
st N
ame
Firs
tM
IHi
ghes
t Deg
ree
Depa
rtmen
t (in
clud
e un
it no
.)
Spec
ialty
Inst
itutio
n
MD
Ande
rson
Em
ploy
ee ID
No.
(req
uire
d fo
r all
MDA
CC e
mpl
oyee
s):
Phys
icia
n Y
es
No
Stre
et
City
Stat
e/Fo
reig
n Co
untry
/Zip
or M
ail C
ode
Dayt
ime
Phon
e (w
ith a
rea
code
) Ce
ll Ph
one
(with
are
a co
de)
Fax
(with
are
a co
de)
E-m
ail A
ddre
ss (
plea
se p
rint)
Emer
genc
y Co
ntac
tPh
one
(with
are
a co
de)
Cred
it Ca
rd H
olde
r Nam
e (F
irst/
Last
) Ch
arge
the
follo
win
g: V
ISA
M
C
AM
EX
Cred
it Ca
rd N
umbe
rEx
pira
tion
Date
Secu
rity
Code
/CVV
/CSV
Cred
it Ca
rd H
olde
r Bill
ing
Addr
ess
& Z
IP C
ode
MD
And
erso
n In
terd
epar
tmen
tal T
rans
fer (
IDT)
No.
: *F
und
Grou
p 90
will
not
be
acce
pted
Bus
ines
s U
nit
D
epar
tmen
tFu
nd G
roup
*Fu
ndFu
nd T
ype
Aut
hori
zed
Sign
atur
e RE
QU
IRED
for C
RED
IT C
ARD
or I
DT
IDT
Appr
over
Nam
e (F
irst/L
ast)
plea
se p
rint
THIS
IS N
OT A
SEL
F-M
AILE
R - A
ddre
ss to
: 14
th U
pdat
e on
the
Man
agem
ent o
f Ge
nito
urin
ary
Mal
igna
ncie
sCM
E/Co
nfer
ence
Man
agem
ent –
Uni
t 178
1Th
e Un
ivers
ity o
f Tex
as M
D An
ders
on C
ance
r Cen
ter
PO B
ox 3
0140
7, H
oust
on, T
X 77
230-
1407
or fa
x to
713-
794-
1724
M
ake
chec
k or m
oney
ord
er p
ayab
le to
: Th
e Un
iver
sity
of T
exas
MD
Ande
rson
Can
cer C
ente
r
Regi
stra
tion
Fees
Phys
icia
ns (M
D’s
/DO
’s) a
nd S
cien
tists
...
....
..$2
75
Stud
ents
/ Tr
aine
es /
PAs
/ A
dvan
ced
Nur
se P
ract
ition
ers .
....
....
....
....
.$60
One
Day
Fee
...
....
....
....
....
....
....
....
...$30
o
Nov
embe
r 1o
Nov
embe
r 2
Will
you
be
atte
ndin
g th
e Fr
iday
eve
ning
rece
ptio
n?
oYe
so
No
CME/
Conf
eren
ce M
anag
emen
t- Un
it 17
81Th
e Un
iver
sity
of T
exas
MD
Ande
rson
Can
cer C
ente
r17
6700
/30/
1217
19/4
1PO
Box
301
407
Hous
ton,
TX
7723
0-14
07
Non
-Pro
fit O
rg.
U.S.
Pos
tage
P A
I DHo
usto
n, T
XPe
rmit
No.
705
2
Top Related